The news about Pfizer's adolescent trial is excellent. As some debate whether we have enough data to reliably estimate vaccine efficacy in this subgroup, some important context is that efficacy was not even the primary outcome of the trial. 1/4 https://t.co/9UWTqn5122
— Natalie E. Dean, PhD (@nataliexdean) March 31, 2021
Tagged COVIDVaccine studies